E-SCIENCE WEBINAR 6
Individualised treatment of patients with Angina and HF: where do we stand after ESC 2021?
on 14th of October at 14h CET (Paris time)
Giuseppe-Rosano-Pic
user
Prof G. Rosano
(UK)
Prof. J Tan
user
Prof J. Tan (tbc)
(Singapore)
Giuseppe-Rosano-Pic
user
Juan Prof G. Rosano
UK
Prof. J Tan
user
Juan Prof J. Tan (tbc)
Singapore
Thank you for joining webinar
Recent data about coronary revascularization and medical therapy: implications in clinical practice
9 July 2021 – 14.00-15:30 CEST (Paris time)
( Chair )
Filippo
user
Filippo Crea,
Italy
Reappraisal of optimal medical therapy vs PCI in chronic coronary syndromes
Mutlu
user
Bülent Mutlu,
Turkey
Clinical case discussion
Abdelhamid.Magdy
user
Magdy Abdelhamid
(Egypt)
Panel discussion with speakers and international discussants
circle-cropped31.png
user
Luis Henrique Gowdak
(Brazil)
Panel discussion with speakers and international discussants
in collaboration with
Filippo
Past webinar
E-Science Webinar 02
Management of post-PCI Angina
12th March 2021
E-Science Webinar 03
Personalized Management of angina
20th April 2021
E-Science Webinar 04
Angina management in clinical practice: from prevention to symptoms control
27th of May -2021
Thank you for joining the E-Science Webinar 04
The next webinar will be on the 9th of July 2021, Keynote speaker : Prof Filippo Crea, Italy
in collaboration with
E-Science webinar 2
Management of post-PCI Angina
12 March 2021
circle-cropped2 op
user
Giuseppe Rosano UK
Abdelhamid.Magdy
user
Magdy Abdelhamid Egypt
circle-cropped3 op
user
Luis Henrique W. Gowdak Brazil
user
Interactive Discussion

new-cover-bg
Past Webinar

E-Science Webinar 02
Management of post- PCI Angina
of angina
12th March 2021

line2 View webinar
E-Science Webinar 03

Personalized Management
of angina
20th April 2021
View webinar
E-Science Webinar 04

Angina management in clinical practice:
from prevention to symptoms control
27th of May -2021
View webinar line2
calanderSeptember 2021

Congress coverage: ESC 2021


Editor-image

Findings of the RIPCORD 2 study: does routine pressure wire assessment influence management strategy of coronary angiography for diagnosis of chest pain? Presented by Nicholas Curzen, UK
Source: ESC TV

calanderBy G. Bozet, MDcalander5 September 2021

IN THE LITERATURE THIS WEEK


Featured image

Implications of blinding: quality of life in trials of revascularisation for chronic stable angina

In stable coronary artery disease, medications are used for 2 purposes: cardiovascular risk reduction and symptom and Quality of Life (QoL) improvement. In clinical trials and clinical practice, medication use is often not optimal.

Conventional teaching, clinical experience, and unblinded trials tell us that revascularisation improves quality of life but this was not supported by the only blinded trial of PCI, ORBITA (Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in…

calanderBy Dr. Williamcalander23 December 2020

Medical Education


Angina ccs guidlines

There have been no landmark trials necessitating a major change regarding the drugs recommended for angina treatment since the 2013 guidelines. Newer second-line drugs such as nicorandil, ranolazine, ivabradine and trimetazidine, have class IIa recommendations when symptoms are not adequately controlled by first-line drugs and nitrates.

calanderBy Dr. Jadecalander23 December 2020

Angina In the world


Angina in brazil

Antithrombotic therapy: In earlier guidelines, aspirin was recommended in all patients with coronary artery disease. In the 2019 guideline, it is stated that “Aspirin 75‐100 mg daily is recommended in patients with a previous MI or revascularization and “Aspirin 75‐100 mg daily may be considered in patients without a history of MI or revascularization, but with definitive evidence of CAD on imaging.

Featured image
calanderBy Prof. Fausto Pintocalander5 September 2021
Prof. Fausto Pinto; Comment on a recent study published in the EHJ (European Heart Journal) by Navarese and colleagues

During the HFA conference in Florence, Italy, Prof. Fausto Pinto (Head of the cardiology department at the University Hospital in Lisbon, past president of the ESC and president of the World Heart Federation) commented on a recent study published in the EHJ (European Heart Journal) by Navarese and colleagues. This systematic review and meta-analysis compared the differences between 2 strategies in managing stable patients with coronary artery disease: elective coronary revascularization plus medical therapy over medical therapy alone and the results are quite interesting.

Featured image
calanderBy Prof. C Rosanocalander8 July 2021
PATIENTS WITH HEART FAILURE AND ISCHEMIC HEART DISEASE

Prof Rosano from Florence during HFA conference 2021.During the Heart Failure 2021 & World Congress on Acute Heart Failure held in Florence from 29 June to 1st July 2021, Prof Rosano discusses recommendations for patients with heart failure and ischemic heart disease.

Featured image
calanderBy admincalander9 April 2021
Angina pectoris: what should patients know

Anginal pain is the alarm system of the heart. Prof Vinereanu, Romania provides a reminder about angina pectoris and what all patients should know. He focuses on the patients journey, and the important role of lifestyle interventions

RSS Follow latest articles on microvascular angina
Featured image
calanderBy Prof. G Rosanocalander16 September 2021
Patient profiling in heart failure for tailoring medical therapy. The patients with HF and IHD / Angina.

The Heart failure association of the European society of cardiology recently published new guidelines for patients with heart failure as well as a consensus document on patients profiling. A very relevant question for clinical practice is how to implement therapies according to the profiles of…

Featured image
calanderBy D. Beardcalander5 September 2021
Stable angina and NSTEMI: plaque distribution and target vessel vulnerability

There is very little data comparing plaque characteristics and wire-free physiological assessment in the target vessel in patients with stable angina versus acute coronary syndrome.

In this study, K. Dan et al. (USA)investigated the difference in plaque distribution between stable angina and NSTEMI, and explored the relationship between target vessel vulnerability by optical coherence tomography and wire-free functional assessment with quantitative flow ratio.

Featured image
calanderBy G. Bozet, MDcalander2 September 2021
The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins

Dyslipidemia is known to be significantly associated with an increased risk of CAD and lipid-lowering strategy is the key approach for primary and secondary prevention.
In this cohort study, D. Kanda et al. (Kagoshima University, Japan) aimed to examine the clinical meaning of LDL-C <70 mg/dL and non-HDL-C <100 mg/dL on the occurrence of new lesions among Japanese patients with stable angina who were prescribed with strong statins.

Featured image
calanderBy D. Beardcalander2 September 2021
Blood urea nitrogen is associated with long-term all-cause mortality in stable angina pectoris patients: 8-year follow-up results

Elevation of blood urea nitrogen (BUN) indicates renal dysfunction and is associated with increased mortality in cardiovascular diseases.
The authors investigated the relationship between the blood urea nitrogen concentration measured at hospital admission and the long-term all-cause mortality in 344 patients with stable angina pectoris, during a mean follow-up period of 8 yrs.

Featured image
calanderBy admincalander11 June 2021
CONGRESS COVERAGE

E. Navarese et al. (Nicolaus Copernicus University, Poland) presented the results of a new meta-analysis of revascularisation plus medical therapy versus medical therapy alone in patients with chronic coronary syndromes. A total of 19,806 patients with chronic coronary syndromes undergoing elective revascularisation from 25 randomised trials were pooled.

Featured image
calanderBy D. Beardcalander11 June 2021
Management of stable ischaemic heart disease: an overview

This article by Q. Radaideh et a. (Midwest Cardiovascular Research Foundation, USA) reviews the evidence on optimal medical therapy versus coronary revascularization in patients with stable ischaemic heart disease. The recently published ISCHEMIA trial has established the non-inferiority of medical therapy in comparison to coronary revascularisation in patients with moderate to severe ischaemia.

Featured image
calanderBy D. Beardcalander31 May 2021
Cardiac rehabilitation: frailty and coronary syndromes

Frailty and CVD in the elderly share pathophysiological mechanisms and associated conditions, such as malnutrition, sarcopenia, anaemia, polypharmacy and both increased bleeding/thrombotic risk.
In geriatric populations, acute coronary syndromes are associated with an increased frailty degree. Frail elderly patients are increasingly referred to cardiac rehabilitation programs after acute coronary syndromes.

Featured image
calanderBy D. Beardcalander17 May 2021
Cardioprotection in perspective

Despite the increasing use, better logistics and improved methodology of interventional approaches for coronary reperfusion, the mortality and morbidity from acute myocardial infarction are still substantial. This is very clear when examining the real world data. This issue is complex: patients with acute myocardial infarction are typically advanced in age, have comorbidities and are receiving several medications. For them, it is necessary to consider not only infarct size reduction but also attenuation of coronary microvascular obstruction, as well as longer-term targets including infarct repair and reverse remodelling.

Featured image
calanderBy G. Bozet, MDcalander23 March 2021
Health status after conservative care in CAD and advanced kidney disease

In the ISCHEMIA trial, an invasive strategy with angiographic assessment and revascularization did not reduce clinical events among patients with stable ischemic heart disease and moderate or severe ischemia. A secondary objective of the trial was to assess angina-related health status among these patients.

Featured image
calanderBy admincalander16 March 2021
Genetic dysregulation of ET-1 and microvascular dysfunction

T. J. Ford et al. (British Heart Foundation, UK) performed a multimodality investigation into the role of ET-1 and this gene variant in the pathogenesis of coronary microvascular dysfunction in 391 patients with symptoms and/or signs of ischaemia but no obstructive coronary artery disease.

Podcasts


Joints are the areas where two or more bones meet. Most joints are mobile, allowing the bones to move. Joints consist of the following: Cartilage – at the joint, the bones are covered with cartilage (a connective tissue), which is made up of cells and fibers and is wear-resistant. Cartilage helps reduce the friction of movement. Synovial membrane months, and years to a lifetime....
Featured image
calanderBy Dr. Williamcalander23 December 2020
Brazilian Society of Cardiology

biomarkers in angina

Emphasis is placed on the various lifestyle modifications as outlined in the recent lipids and preventive guidelines

Featured image
calanderBy Dr. Zephcalander23 December 2020
AHA 2021

What’s new in 2021

Despite significant advances in medical technology and pharmacology, cardiovascular disease remains a leading

Video


Video
author By Prof. G Rosano calander 17 September 2021
Cardiovascular disease remains the number one cause of death and disability around the globe.
Featured image
calanderBy Prof. G Rosanocalander16 September 2021
Patient profiling in heart failure for tailoring medical therapy. The patients with HF and IHD / Angina.

The Heart failure association of the European society of cardiology recently published new guidelines for patients with heart failure as well as a consensus document on patients profiling. A very relevant question for clinical practice is how to implement therapies according to the profiles of…

The Heart failure association of the European society of cardiology recently published new guidelines for patients with heart failure as well as a consensus document on patients profiling. A very relevant question for clinical practice is how to implement therapies according to the profiles of the patients. Some have heart failure and ischemic heart disease/angina. Prof Rosano, UK shares some recent information.

Featured image
calanderBy Prof. Fausto Pintocalander5 September 2021
Prof. Fausto Pinto; Comment on a recent study published in the EHJ (European Heart Journal) by Navarese and colleagues

During the HFA conference in Florence, Italy, Prof. Fausto Pinto (Head of the cardiology department at the University Hospital in Lisbon, past president of the ESC and president of the World Heart Federation) commented on a recent study published in the EHJ (European Heart Journal) by Navarese and colleagues. This systematic review and meta-analysis compared the differences between 2 strategies in managing stable patients with coronary artery disease: elective coronary revascularization plus medical therapy over medical therapy alone and the results are quite interesting.